Correcting such inefficient Ca2+ handling by overexpressing the SERCA2a gene [6], [7] or perturbing its endogenous inhibitor, PLN [8], [9], [10], successfully restored cardiac function and ameliorated heart failure progression in a variety of experimental animal models, clearly demonstrating that SERCA/PLN is a promising therapeutic target. Here, PLN is linked to heart failure.